Pfizer stock: fundamental analysis
Stocks · PFE · Healthcare
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. Below are its fundamentals, explained in the order worth reading them: business quality, debt, growth and, last, whether the price is reasonable.
- Price: 27.66 USD
- Market cap: 157.7B USD
Data as of September 18, 2026 · Yahoo Finance
Quick read
Business quality
ROE of 5.0%: a low return on shareholders' money. Out of every 100 in sales, 6.8 end up as profit.
Financial health
Net debt/EBITDA of 2.0x: moderate leverage, manageable for stable businesses such as utilities or infrastructure.
Growth
Revenue is growing 2.6% year on year: modest growth.
Valuation
It trades at a P/E of 36.4, in line with the 33.9 median of the healthcare companies we track. On expected earnings the P/E falls to 9.5: the market expects profits to rise.
Dividend
Dividend yield of 6.2% (1.72 USD per share per year) with a payout ratio of 226.3%. It pays out nearly all (or more) of its earnings: watch whether the dividend is sustainable.
Tools
All metrics
| Pfizer | Sector median | |
|---|---|---|
| Business quality | ||
| ROE | 5.0% | 25.7% |
| ROA | 5.8% | 9.0% |
| Gross margin | 74.7% | 70.5% |
| Operating margin | 27.9% | 28.5% |
| Net margin | 6.8% | 15.6% |
| Financial health | ||
| Net debt/EBITDA | 2.0x | 2.0x |
| Debt/equity | 0.7x | 0.7x |
| Current ratio | 1.3x | 1.3x |
| Growth | ||
| Revenue growth | 2.6% | 10.2% |
| Earnings growth | — | 139.8% |
| Valuation | ||
| P/E ratio | 36.4x | 33.9x |
| Forward P/E | 9.5x | 16.7x |
| EV/EBITDA | 8.3x | 17.0x |
| Price/book | 1.9x | 4.2x |
| FCF yield | 7.9% | 4.7% |
| Dividend | ||
| Dividend yield | 6.2% | 1.8% |
| Payout ratio | 226.3% | 48.0% |
| Beta (volatility) | 0.3x | 0.3x |
Frequently asked questions
What is Pfizer's P/E ratio?
Pfizer's P/E is 36.4 based on trailing 12-month earnings and 9.5 on expected earnings. The median for its sector among the companies we track is 33.9. Data as of September 18, 2026.
What dividend does Pfizer pay?
Dividend yield of 6.2% (1.72 USD per share per year) with a payout ratio of 226.3%. It pays out nearly all (or more) of its earnings: watch whether the dividend is sustainable.
Is Pfizer stock expensive?
It trades at a P/E of 36.4, in line with the 33.9 median of the healthcare companies we track. On expected earnings the P/E falls to 9.5: the market expects profits to rise. This is an educational reading based on ratios, not a buy or sell recommendation.
Does Pfizer have a lot of debt?
Net debt/EBITDA of 2.0x: moderate leverage, manageable for stable businesses such as utilities or infrastructure.
What is Pfizer's market cap?
Pfizer has a market cap of 157.7B USD and its shares trade at 27.66 USD, with a 52-week range of 23.58 USD to 29.21 USD (data as of September 18, 2026).
Other companies in the sector
Trailing 12-month metrics. Educational content, not investment advice.